12:00 AM
 | 
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Halaven eribulin mesylate regulatory update

Eisai said Italy granted reimbursement for Halaven eribulin mesylate to treat locally advanced or metastatic breast cancer in patients who have...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >